Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	33.79	43.05	65.47	112.35	4.21
Short-Term Investments	35.71	24.69	17.38	-	-
Cash & Short-Term Investments	69.5	67.74	82.85	112.35	4.21
Cash Growth	2.60%	-18.24%	-26.26%	2566.65%	30.96%
Accounts Receivable	10.18	16.12	7.19	1.42	2.44
Other Receivables	0.33	1.26	1.11	0.11	0.14
Receivables	10.51	17.38	8.3	1.53	2.58
Inventory	1.97	-	-	-	-
Prepaid Expenses	4.05	1.82	1.69	0.89	0.66
Restricted Cash	-	-	-	-	0.11
Other Current Assets	-	-	-	0.29	0.83
Total Current Assets	86.03	86.94	92.83	115.06	8.38
Property, Plant & Equipment	1.01	1.53	1.78	2.03	2.39
Long-Term Investments	6.01	-	20	15.42	-
Goodwill	4.7	4.7	-	-	-
Other Intangible Assets	68.99	69.23	-	-	-
Long-Term Accounts Receivable	-	-	-	-	0.4
Other Long-Term Assets	11.38	9.94	0.72	0.44	0.04
Total Assets	178.13	172.33	115.34	132.94	11.21
Accounts Payable	13.08	13.99	3.61	0.52	1.17
Accrued Expenses	17.37	18.97	7.21	2.52	5.47
Short-Term Debt	-	37.7	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	0.39
Current Portion of Leases	0.42	0.54	0.49	0.37	0.5
Other Current Liabilities	3.2	2.52	0.71	0.82	-
Total Current Liabilities	34.07	73.72	12.02	4.23	7.54
Long-Term Debt	59.5	5.07	12.8	-	68.05
Long-Term Leases	0.37	0.46	0.84	1.24	1.61
Other Long-Term Liabilities	44.52	31.22	14.55	0.36	0.43
Total Liabilities	138.46	110.46	40.22	5.82	77.62
Common Stock	0.01	0	0	0	-
Additional Paid-In Capital	555.3	472.66	436.27	396.96	192.06
Retained Earnings	-505.29	-399.78	-353.73	-267.03	-258.47
Treasury Stock	-10.98	-10.98	-7.54	-2.81	-
Comprehensive Income & Other	0.63	-0.04	0.11	-	-
Total Common Equity	39.67	61.86	75.12	127.12	-66.41
Shareholders' Equity	39.67	61.86	75.12	127.12	-66.41
Total Liabilities & Equity	178.13	172.33	115.34	132.94	11.21
Total Debt	60.3	43.77	14.13	1.61	70.55
Net Cash (Debt)	9.2	23.97	68.72	110.74	-66.33
Net Cash Growth	-61.62%	-65.11%	-37.95%	-	-
Net Cash Per Share	0.20	0.68	1.99	3.72	-16.66
Filing Date Shares Outstanding	54.12	41.85	34.54	34.42	28.38
Total Common Shares Outstanding	53.67	41.53	34.54	35.01	4.54
Working Capital	51.96	13.22	80.81	110.83	0.85
Book Value Per Share	0.74	1.49	2.17	3.63	-14.64
Tangible Book Value	-34.03	-12.06	75.12	127.12	-66.41
Tangible Book Value Per Share	-0.63	-0.29	2.17	3.63	-14.64
Machinery	1.36	1.51	1.28	1.05	1.01
Leasehold Improvements	0.71	0.71	0.71	0.72	0.72

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q